303810 — Dongkook Life Science Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Dongkook Life Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	102,668	107,234	120,161	131,816	130,344
Cost of Revenue
Gross Profit	21,858	22,193	25,260	28,588	32,999
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	95,871	101,004	111,632	119,900	117,298
Operating Profit	6,797	6,230	8,530	11,916	13,045
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,433	5,281	4,830	4,753	10,829
Provision for Income Taxes
Net Income After Taxes	5,858	4,239	4,167	2,245	8,658
Net Income Before Extraordinary Items
Net Income	5,858	4,239	4,167	2,245	8,658
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,858	4,239	4,167	2,245	8,658
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	183	133	110	70	273
Dividends per Share